Unity Biotechnology Inc Quick Ratio (UBX) starting from the first quarter 2025 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Unity Biotechnology Inc   (NASDAQ: UBX)

Unity Biotechnology Inc 's Quick Ratio

UBX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2025, Quick Ratio deteriorated to 1.87 a new company low.

Within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Quick Ratio than Unity Biotechnology Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 55, from total ranking in the fourth quarter 2024 at 602.

Explain Quick Ratio?
How much Cash & cash equivalents UBX´s has?
What are UBX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

UBX Quick Ratio (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1
Y / Y Current Liabilities Change 17.25 % -60.52 % 1.75 % -60.32 % -64.63 %
Y / Y Cash & cash equivalent Change -53.39 % -46.23 % -36.79 % -50.81 % -56.43 %
Quick Ratio MRQ 1.87 2.51 3.31 3.85 4.7
UBX's Total Ranking # 55 # 602 # 575 # 680 # 580
Seq. Current Liabilities Change -2.1 % 5.42 % -0.39 % 14.05 % -67.04 %
Seq. Cash & cash equivalent Change -27.11 % -20 % -14.56 % -6.46 % -15.9 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 7
Healthcare Sector # 13
Overall Market # 55


Quick Ratio Statistics
High Average Low
22.36 7.46 1.87
(Mar 31 2018)   (Mar 31 2025)




Financial Statements
Unity Biotechnology Inc 's Current Liabilities $ 9 Millions Visit UBX's Balance sheet
Unity Biotechnology Inc 's Cash & cash equivalent $ 17 Millions Visit UBX's Balance sheet
Source of UBX's Sales Visit UBX's Sales by Geography


Cumulative Unity Biotechnology Inc 's Quick Ratio

UBX's Quick Ratio for the trailling 12 Months

UBX Quick Ratio

 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -42.09 % -54.58 % -32.55 % -40.1 % -17.71 %
Y / Y Cash & cash equivalent TTM Growth -46.97 % -49.27 % -51.38 % -53.94 % -43.05 %
Quick Ratio TTM 2.87 3.54 2.92 3.28 3.14
Total Ranking TTM # 3259 # 2298 # 2246 # 3181 # 3156
Seq. Current Liabilities TTM Growth 3.86 % -29.1 % 0.31 % -21.6 % -18.55 %
Seq. Cash & cash equivalent TTM Growth -15.83 % -14.01 % -10.6 % -18.04 % -19.48 %

Quick ratio ranking by company, industry and sector >> Back to UBX Financial Strength Comparisons >> Go to Compare UBX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2025 to $9.07 millions, cumulative Quick Ratio decreased to 2.87 below the Unity Biotechnology Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 435 other companies have achieved higher Quick Ratio than Unity Biotechnology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 2298 to 3259.

Explain Quick Ratio?
How much Cash & cash equivalents UBX´s has?
What are UBX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 436
Healthcare Sector # 900
Within the Market # 3259


trailing twelve months Quick Ratio Statistics
High Average Low
14.04 6.67 2.18
(Mar 31 2019)   (Mar 31 2018)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Forte Biosciences Inc   5.08 $ 45.856  Millions$ 9.032  Millions
Madrigal Pharmaceuticals Inc   5.07 $ 843.068  Millions$ 166.221  Millions
Prelude Therapeutics Inc  5.01 $ 99.074  Millions$ 19.787  Millions
Cogent Biosciences Inc   4.98 $ 245.661  Millions$ 49.318  Millions
Aldeyra Therapeutics Inc   4.94 $ 39.707  Millions$ 8.031  Millions
Hepion Pharmaceuticals Inc   4.90 $ 4.586  Millions$ 0.936  Millions
Silo Pharma Inc  4.90 $ 5.451  Millions$ 1.113  Millions
Aclaris Therapeutics Inc   4.90 $ 105.314  Millions$ 21.514  Millions
Pepgen Inc   4.79 $ 97.781  Millions$ 20.431  Millions
Genelux Corporation  4.77 $ 35.102  Millions$ 7.352  Millions
Corvus Pharmaceuticals Inc   4.76 $ 44.212  Millions$ 9.279  Millions
Scynexis Inc   4.76 $ 40.607  Millions$ 8.532  Millions
Cns Pharmaceuticals Inc   4.69 $ 13.048  Millions$ 2.779  Millions
Abeona Therapeutics Inc   4.68 $ 84.155  Millions$ 17.983  Millions
Transcode Therapeutics Inc   4.65 $ 11.681  Millions$ 2.510  Millions
Mural Oncology Plc  4.65 $ 107.682  Millions$ 23.153  Millions
United Therapeutics Corporation  4.60 $ 3,321.300  Millions$ 721.500  Millions
Lantern Pharma Inc   4.60 $ 19.722  Millions$ 4.286  Millions
Kiora Pharmaceuticals Inc   4.57 $ 24.106  Millions$ 5.275  Millions
Bullfrog Ai Holdings Inc   4.53 $ 3.802  Millions$ 0.839  Millions
Maravai Lifesciences Holdings Inc   4.51 $ 285.053  Millions$ 63.158  Millions
Kairos Pharma Ltd   4.49 $ 3.616  Millions$ 0.805  Millions
Q32 Bio Inc   4.49 $ 65.483  Millions$ 14.579  Millions
Arvinas Inc   4.46 $ 954.300  Millions$ 214.000  Millions
Arcturus Therapeutics Holdings Inc   4.39 $ 216.948  Millions$ 49.409  Millions
Damora Therapeutics Inc   4.33 $ 11.939  Millions$ 2.755  Millions
Hutchmed china Limited  4.33 $ 1,367.275  Millions$ 315.775  Millions
Milestone Pharmaceuticals Inc   4.32 $ 55.958  Millions$ 12.963  Millions
Sinovac Biotech Ltd  4.31 $ 6,639.502  Millions$ 1,540.365  Millions
Cocrystal Pharma Inc   4.27 $ 6.921  Millions$ 1.622  Millions

Date modified: 2026-09-08T22:42:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.